2/2/2024 0 Comments Colol rectal cancer and hivKeywords: Metastatic Colorectal Cancer, FOLFOX4, HIV-infection, HAART, chemotherapy, treatment This study suggests the good tolerability of the FOLFOX4, making it a reasonable option for combination with HAART. Moreover, the concomitant use of HAART did not seem to increase the FOLFOX4 toxicity. FOLFOX4 plus concomitant HAART resulted feasible and active also in HIV-seropositive patients. Conclusions: To our knowledge, this is the largest study describing activity and tolerability of FOLFOX4 and HAART, in this setting. The medi+ count was 380 (range 220-570) at diagnosis. No opportunistic infections occurred during or immediately after chemotherapy. An overall response rate of 50% was observed 4.2% of patients achieved complete response and 45.8% partial response. Results: Four median cycles of chemotherapy were administered the most common severe toxicity was neutropenia (37.5%). Patients and Methods: From January 2002 to March 2007, 24 patients were selected among the CRC HIV-seropositive patients treated with FOLFOX4 and concomitant HAART within the Italian Cooperative Group on AIDS and Tumors (GICAT). The results were analyzed to evaluate feasibility and activity of FOLFOX4 plus highly active antiretroviral therapy (HAART) in metastatic CRC (mCRC) HIV-seropositive patients. Background: Although FOLFOX4 is considered the standard chemotherapy regimen for colorectal cancer (CRC), few data are available on its results in human immunodeficiency (HIV)-related CRC.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |